市場調査レポート
商品コード
1084355
インスリン送達デバイスの世界市場の動向・予測 (2022年~2028年):製品タイプ・流通チャネル・地域別Insulin Delivery Devices Market, by Product Type, Distribution Channel, and Geography - Global Trends, and Forecast, 2022 - 2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
インスリン送達デバイスの世界市場の動向・予測 (2022年~2028年):製品タイプ・流通チャネル・地域別 |
出版日: 2022年05月27日
発行: Coherent Market Insights
ページ情報: 英文 150 Pages
納期: 2~3営業日
|
インスリン送達デバイスの市場は、糖尿病患者の増加や設計面での新たな技術革新により、大きな牽引力を得ています。WHOによると、2021年には、世界で推定4億2,200万人の成人が糖尿病に罹患しています。過去10年間における2型糖尿病の発症率の大きな急増は、主に肥満の拡大に起因しています。一方で、一部のインスリン送達デバイスが高コストであり、市場成長の抑制要因になると予想されています。
当レポートでは、世界のインスリン送達デバイスの市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、技術動向、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。
Direct subcutaneous insulin injection are the most common form of drug delivery, using a needle and syringe. There are different types of insulin delivery devices available including, syringes, pens, jet injectors, and insulin pumps. Insulin can be packaged in vials (bottles), cartridges or prefilled pens. However, several disposable and reusable pen devices have been developed that provide options for delivering rapid insulins and insulin premixes. Type or dosage of insulin can be changed according to the requirements to meet the individual needs of the patient Manufacturers are focusing on designing products, which are cost effective for people with diabetes which is expected to propel the growth of the insulin delivery devices market. For instance, in July 2017, Becton, Dickinson and Company launched BD Viva pen needles, have a highly engineered needle tip design for improved comfort and considered as the most cost-effective option for insulin-injecting people with diabetes in the UK.
The market is gaining significant traction due to increasing prevalence of diabetes, and new innovations in terms of design. According to the World Health Organization, in 2021, an estimated 422 million adults are living with diabetes globally. The major spike in incidence of type 2 diabetes over the last decade is mainly attributed to rising prevalence of obesity. However, high cost of some insulin delivery devices is expected to be a restraining factor for the market growth. For instance, insulin analogs supplied in cartridges or prefilled pens have a higher per unit of insulin cost than insulin analogs supplied in vials. For example, one vial (1000 U) of insulin costs US$ 105.95, which equates to a cost of 10.6 cents per unit of insulin. Five prefilled insulin pens containing insulin glulisine (total of 1500 U) have a total cost of US$ 201.01, equating to a cost of 13.4 cents per unit of insulin (26% over the cost of insulin glulisine supplied in a vial).
This report provides in-depth analysis of the insulin delivery devices market and its application, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global insulin delivery devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies and future plans
Key companies covered as a part of this study include Novo Nordisk A/S, Becton, Dickinson and Company, Sanofi S.A.., F. Hoffmann-La Roche, Ltd., Eli Lilly and Company, Medtronic, Plc, Ypsomed Holding AG, Animas Corporation, and Insulet Corporation.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion, and marketing tactics.
The global insulin delivery devices market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of insulin delivery devices, research and consulting firms, new entrants, and financial analysts
Various strategy matrices used in analyzing the insulin delivery devices market would provide stakeholders vital inputs to make strategic decisions accordingly
Global Insulin Delivery Devices Market, By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
Global Insulin Delivery Devices Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Insulin Delivery Devices Market, By Geography:
North America
By Country:
U.S.
Canada
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
China
India
Japan
ASEAN
Australia
South Korea
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country:
North Africa
Central Africa
South Africa
By Product Type:
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Jet Injectors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Novo Nordisk A/S*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Future Plans
Becton, Dickinson and Company
Sanofi S.A.
F. Hoffmann-La Roche, Ltd.
Eli Lilly and Company
Medtronic, Plc
Ypsomed Holding AG
Animas Corporation
Insulet Corporation
“*” marked represents similar segmentation in other categories in the respective section.